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Available online 2 March 2016AbstractObjectives: Little is currently known about the issues surrounding management and treatment of severe osteoporosis in South Korea. Our
objective was to assess doctors' views on the perception, diagnosis, and treatment of severe osteoporosis.
Methods: Face-to-face interviews were conducted (16 Februarye13 March 2015) with 100 doctors (specialists in orthopedic surgery, endo-
crinology, neurosurgery, family medicine, or rheumatology) who treated 5 severe osteoporosis (T-score  2.5, plus fracture) patients per
month. Respondent demographic characteristics, their perception of severe osteoporosis, its impact and treatment, and their views on current
practice and unmet needs were assessed.
Results: Of 416 doctors approached, 100 completed the survey (24% response rate). Most doctors (90%) specialized in orthopedic surgery,
endocrinology, or neurosurgery. When diagnosing severe osteoporosis, most doctors (79%) considered both bone mineral density and fracture.
Almost all doctors (91%) ranked disease impact and seriousness highly, but much fewer (25%) doctors thought society agreed. Most doctors
(89%) had concerns with current treatments, switching treatments because of the efficacy and safety of bisphosphonates (>89%), the efficacy of
selective estrogen receptor modulators (>71%), and the high cost of parathyroid hormone (>73%). Parathyroid hormone was ranked highest for
efficacy and was preferentially prescribed to severe osteoporosis patients (mean 32.2% of prescriptions) compared with osteoporosis patients
overall (3.7%). “Limitations with reimbursement” was the most commonly cited (76%) unmet need.
Conclusions: There are concerns with the safety, efficacy, and affordability of current treatments for severe osteoporosis in South Korea, as well
as a perceived lack of disease awareness amongst patients and doctors.
© 2016 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).especially hip fractures, are associated with substantial
disability, morbidity, mortality, and economic cost [2].
Furthermore, the presence of a fracture is associated with
increased risk of future fracture; hence, reduction of this
fracture risk and its concomitant impact on health is one of the
main goals of treatment [3].
In South Korea, osteoporosis is a growing health and
economic concern that requires improved management. Osteo-
porosis is estimated to affect 38% of women and 7.3% of menElsevier B.V. This is an open access article under the CC BY-NC-ND license
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comparing the age-standardized incidence of hip fractures in 62
countries suggested that the incidence rate in South Korea (231
per 100,000 population) may be one of the highest reported in
Asia (only Taiwan [264 per 100,000)] and Singapore [248 per
100,000] are higher) and may be higher than the rates in some
countries in Europe and North America (for example, United
Kingdom: 201 per 100,000; Canada: 211 per 100,000) [5].
Moreover, the proportion of the SouthKorean population over 50
years of age is expected to increase from 33% in 2013 to 57% by
2050, substantially expanding the number of osteoporosis pa-
tients [6]. The costs associated with osteoporosis and osteopo-
rotic fractures in 2010 were 796 billion Korean Republic Won
(707 million USD) and are predicted to increase [7]. However,
South Korea, like many countries, has shown suboptimal use of
osteoporosis treatments in patients with hip fracture [1]. More
effective strategies to manage the increasing numbers of
osteoporosis-related fractures in South Korea are urgently
needed.
In order to improve management of osteoporotic fractures
in South Korea, it is essential to evaluate the views held by
doctors directly responsible for treating osteoporosis. A
recent survey examined doctors' attitudes to several
osteoporosis-related issues, including screening methods,
secondary osteoporosis, long-term bisphosphonate (BP) use,
and barriers to treatment [8]. However, this survey by Ha and
coworkers did not distinguish between osteoporosis with and
without fracture, nor did it consider the opinions of doctors
on commonly used treatments for osteoporosis other than
BPs. The presence of a fracture, combined with a
T-score  2.5 standard deviations (SD) below the mean
bone mineral density (BMD) of a young adult, has been
classified as severe osteoporosis [9]. Given the serious impact
of osteoporotic fractures on health and society, doctors' per-
spectives, specifically on the awareness, diagnosis, manage-
ment, and treatment of severe osteoporosis, require further
investigation.
Therefore, the aim of our study was to assess perceptions of
severe osteoporosis amongst doctors in South Korea, including
their views of the disease and its impact, their concerns with
current treatments, and their views on the areas of disease
management that require improvement.
2. Materials and methods2.1. Study designThis survey consisted of face-to-face interviews with doc-
tors in South Korea between 16 February and 13 March 2015.
A sample size of 100 respondents was chosen and Gallup
Korea (Seoul, South Korea), a market research company, was
employed to carry out the interviews with doctors, through the
use of paid assistants. Survey responses and the identities of
the respondents were kept confidential, and doctors surveyed
were provided with an honorarium for their participation. The
study was conducted in compliance with the ethical principles
of the Declaration of Helsinki.2.2. Study populationA purposive sampling method was used to identify po-
tential survey respondents who were members of academic
societies related to orthopedics, endocrinology, neurosurgery,
and rheumatology. To achieve a representative sample of
doctors involved in osteoporosis treatment, a minimum of 20
respondents was required to be drawn from each of the three
specialties reported to diagnose and treat large numbers of
osteoporosis patients (based on data from the Health Insur-
ance Review and Assessment Service [10]): orthopedic sur-
gery, endocrinology, and neurosurgery. Survey responses
from specialists in family medicine and rheumatology were
also considered, but a minimum number of respondents from
these two specialties was not required. The survey was dis-
continued or the data were not included for analysis if the
doctors were working outside of a university hospital or a
general hospital, did not have orthopedic surgery, endocri-
nology, neurosurgery, family medicine, or rheumatology as
their primary medical specialty, or if they treated, on average,
fewer than five patients with severe osteoporosis (T-
score < 2.5; 1 previous fracture) per month. With these
criteria, the aim of the study was to obtain viable responses
from 100 doctors.2.3. Questionnaire developmentThe questionnaire was in Korean and consisted of four parts:
(i) demographic characteristics, (ii) perception of severe oste-
oporosis, its impact, and its treatment, (iii) current practice, and
(iv) unmet needs (English language translation of questionnaire
provided in Supplementary Material). The demographic char-
acteristics of the respondents were assessed using questions
based on a survey of doctors in South Korea conducted by Ha
and coworkers [8]. The study authors and Gallup Korea devel-
oped the questions in parts (ii)e(iv) of the questionnaire. The
survey consisted of open-ended questions, multiple-choice
questions (most of which accepted multiple responses), and
rank order questions. Doctors were also asked to rate various
topics on a 5-point Likert scale. When assessing satisfaction
with different treatment aspects, a rating of 1 indicated “not
satisfied” and 5 indicated “very satisfied”. Similarly, for doctors'
perceptions of different aspects of disease, a rating of 1 was
“low” and 5 was “high”. The questionnaires were completed
through face-to-face interviews, which lasted approximately
15 min.2.4. Survey outcomesThe demographic characteristics of the doctors surveyed,
including gender, age, type and years of experience in spe-
cialty, hospital type, and number of osteoporosis patients seen
per month, were recorded. Doctors were then asked to define
their criteria for the diagnosis of osteoporosis and to compare
their views against society's views of the disease and its
impact. Doctors' perceptions of the issues associated specif-
ically with severe osteoporosis (as opposed to osteoporosis in
Table 1
Demographic profile of doctors interviewed (N ¼ 100)
Characteristics n
Gender
Male 84
Female 16
Age
30 to <40 years 17
40 to <50 years 58
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were also recorded. Doctors quantified the proportion of each
of the three main osteoporosis treatments they prescribed, as
well as their levels of satisfaction with various aspects of each
treatment. The concerns that doctors had with each treatment
and their reasons for switching to different treatments or
maintaining current treatments were then explored in detail.
Lastly, doctors were asked to outline aspects of treatment that
they thought required improvement.50 to <60 years 22
60 years 32.5. Analysis
Specialty
Orthopedic surgery 40
Endocrinology 30
Neurosurgery 20
Family medicine 7
Rheumatology 3
Years in specialty
5 to <10 years 26
10 to <20 years 52
20 to <35 years 22Gallup Korea was responsible for collecting and compiling
the survey responses. For questions in which respondents failed
to provide at least one answer, the percentage of responses was
still calculated based on a total sample size of 100. Survey
responses were summarized using descriptive statistics, but no
comparative statistical analyses were carried out.
3. Results
Hospital type
University hospital 48
General hospital 52
3.1. Survey response rateGeographic region
Seoul 63
Gyeonggi 29
Incheon 8
Average number of osteoporosis patients per month
<100 patients 42
100 to <200 patients 37A total of 416 doctors were approached and 100 doctors
who treated at least five patients with severe osteoporosis per
month completed the interview (response rate of 24%). Most
of the remaining 316 doctors were excluded during the initial
screening (see Supplementary Material for survey screening
questions Q1 to Q8).200 patients 21
Average number of osteoporosis patients with fracture per month3.2. Demographic profile of doctors surveyed
5 to <15 patients 8
15 to <30 patients 42
30 to <100 patients 37
100 patients 13
Average number of severe osteoporosis patients per month by specialty
Orthopedic surgery 59.4 (49.6% of all OP)
Endocrinology 33.8 (27.1% of all OP)
Neurosurgery 37.9 (29.5% of all OP)
Family medicine 45.0 (40.4% of all OP)
Rheumatology 28.3 (32.7% of all OP)
As the total number of respondents (N ) was 100, n represents both the number
of respondents and the percentage of respondents in each category, except forDoctors from five different specialties were interviewed,
representing a number of different ages, years in specialist
practice, and number of osteoporosis patientsmanaged (Table 1).
The majority of doctors were male (84%), more than half
were aged between 40 and <50 years (58%), and half had
spent between 10 and <20 years in their specialty (52%).
Substantial representation of specialists in orthopedic surgery,
endocrinology, and neurosurgery was achieved, as planned,
along with a smaller number of specialists in family medicine
and rheumatology.the category listing the average number of severe osteoporosis patients per
month by specialty, where the percentage of patients with severe osteoporosis
is listed in brackets. Abbreviation: OP, osteoporosis patients.
3.3. Number of patients managedOn average, patients with severe osteoporosis constitutedmore
than one third of the osteoporosis patients managed by doctors in
the survey. Orthopedic surgeons managed the highest average
number of severe osteoporosis patients per month, which consti-
tuted close to half of their total osteoporosis patients (Table 1).3.4. Definition and perception of severe osteoporosisThe majority of doctors (79%) indicated that the criteria for
diagnosing severe osteoporosis included both the BMD
(T-score) and presence of a fracture. When asked to provide
the threshold values for BMD, fracture number, and agerequired for a diagnosis of severe osteoporosis, the most
common responses were one fracture (86%), T-scores of 3.0
(42%) or 2.5 (40%), and age brackets of 65e69 years (43%)
or 70e74 years (22%). In ranking these factors in order of
importance for diagnosing osteoporosis, 52% of respondents
ranked fracture as most important, followed by BMD (47%).
Fracture and BMD were ranked either first or second in
importance by 96% and 93% of doctors, respectively.
There was a large difference between doctors' perceptions of
severe osteoporosis and how doctors thought society perceived
Fig. 1. Doctors' perceptions (red) of aspects of severe osteoporosis compared
with their view of society's perceptions (blue).
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of severe osteoporosis and its impact on quality of life as either 4
or 5 (with 1 being the lowest and 5 the highest). In contrast, few
doctors (25%) thought that society ranked the seriousness ofthe disease and its impact on quality of life as high. Similarly,
more than half (68%) of the doctors surveyed ranked the eco-
nomic burden and urgency of treatment associated with severe
osteoporosis as either 4 or 5, whereas less than half (36%)
thought that society would rank these aspects as high.3.5. Impact of severe osteoporosis and treatment goalsMore than half of the doctors (65%) thought that patients
with osteoporotic fracture (severe osteoporosis) would
experience differences in treatment and disease conditions
compared to those without a fracture. Doctors thought that
patients with fracture required more active treatment (43.1%)
and experienced limitations with reimbursement of treatment
(33.8%). These patients were also thought to experience
greater impact on their quality of life due to disease or a lack
of recognition of the seriousness of the disease (16.9%), in
addition to problems with treatment efficacy and safety
(10.8%). Doctors indicated that their patients with severe
osteoporosis experienced serious disability (37.8%), addi-
tional fractures (29.6%), extended recovery time from
surgical procedures (27.6%), economic difficulty (25.3%),
and death (3.9%). When asked to rank the importance of
treatment goals for severe osteoporosis, the majority of
doctors (82.0%) ranked prevention of fracture as most
important, followed by improvement of BMD (12.0%),
and pain relief (6.0%).3.6. Treatments for severe osteoporosisA range of osteoporosis treatments are available in South
Korea, many of which are eligible for reimbursement
(Supplementary Material). In addition to vitamin D and
calcium supplementation, the most commonly prescribed
treatments for osteoporosis were BPs, selective estrogen re-
ceptor modulators (SERMs), and parathyroid hormone
(PTH). Of the three treatments, PTH constituted a much
higher (almost 10-fold) proportion of treatments prescribed
to patients with severe osteoporosis, compared with osteo-
porosis overall (Fig. 2). Unlike PTH, there was little or no
difference in the proportion of BPs or SERMs prescribed for
severe osteoporosis compared with osteoporosis overall.
Doctors were asked to indicate their level of satisfaction with
various aspects of BPs, SERMs, and PTH (Fig. 3). In terms of
treatment cost, patient compliance, and a lack of serious side
effects, SERMs were rated highest, whereas PTH was rated
highest in terms of prevention of further fracture, improve-
ment of BMD and markers of bone metabolism, and efficacy
(pain relief). Notably, doctors were far less satisfied with
PTH in terms of treatment cost and reimbursement,
compared with BPs and SERMs.3.7. Doctors' concerns with treatmentAlmost all doctors (89.0%) expressed concerns with treat-
ments for severe osteoporosis. The two most commonly raised
concerns were safety (66.3%) and efficacy (64.0%), followed
Fig. 2. The proportion of BPs, SERMs, PTH, vitamin D, and calcium prescribed
for overall osteoporosis (blue) compared with severe osteoporosis (red). Arrows
indicate a large difference in the proportion of PTH prescribed to osteoporosis
patients overall compared with severe osteoporosis patients. Patients may be
prescribed more than one drug at a time. Abbreviations: BPs, bisphosphonates;
SERMs, selective estrogen receptor modulators; PTH, parathyroid hormone.
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others (2.2%). Necrosis of the jaw and atypical fracture of the
femur were the most commonly cited specific concerns with
safety. Each of the three treatments was found to be ineffective
or was not able to be used (unusable) in a subset of patients
(Fig. 4). In this subset of patients, more than half (52.5%)
had their prescriptions switched to another drug class (Fig. 4).
The proportion of patients being treated with SERMs and PTH
who were switched to drugs from a different class was muchFig. 3. Doctors' levels of satisfaction with aspects of BPs (yellow), SERMs (blue), a
compared with BPs and SERMs. Abbreviations: BPs, bisphosphonates; PTH, parahigher (>70%) than for patients being treated with BPs
(52.5%; Fig. 4).3.8. Switched treatmentsFor patients whose prescriptions were switched from BPs,
most were switched to SERMs (Fig. 4). The most common
reason given for switching to SERMs was the side effects of
BPs (100%). Most doctors who prescribed a switch from BPs
to PTH cited PTH's greater efficacy (89.7%). For patients
whose prescriptions were switched from SERMs, almost all
were switched to BPs (Fig. 4). The most common reason given
for switching from SERMs to BPs (71.2%) or to PTH (72.2%)
was lack of efficacy. For patients whose prescriptions were
switched from PTH, most were switched to BPs (Fig. 4). The
most common reason given for switching from PTH to BPs
(74.6%) or SERMs (73.3%) was the high cost of PTH
treatment.3.9. Maintained treatmentsPatients who were not switched were maintained on the
current drug or were prescribed a different brand of drug in the
same class. Ineffective or unusable BP treatment was more
likely to be maintained than ineffective or unusable SERM or
PTH treatment. The most common reason provided for
maintaining treatment with BPs and SERMs despite the
existing treatment being ineffective or unusable was a lack ofnd PTH (red). Arrows indicate large differences in satisfaction scores for PTH
thyroid hormone; SERMs, selective estrogen receptor modulators.
Fig. 4. Percentage of patients whose prescriptions were maintained or switched to a different drug class when treatments were deemed ineffective or unusable. The
most common reason for each switch is provided following the percentage of treatments switched to BPs (yellow), SERMs (blue) and PTH (red). Abbreviations:
BPs, bisphosphonates; PTH, parathyroid hormone; SERMs, selective estrogen receptor modulators.
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expense of PTH, side effects of BPs, patient refusal, and that
the use of BPs was better than no treatment, as reasons for not
switching to another drug class and maintaining existing
treatment.3.10. Aspects of treatment that require improvementFrom a list of options (Question 23, Supplementary
Material), the aspect of treatment most commonly identi-
fied by doctors as needing improvement was limitation of
reimbursement (76%). Other aspects of treatment identified
as needing improvement were a lack of recognition of the
seriousness of disease by patients (57%), a lack of variety in
treatment options (50%), treatment efficacy (45%), treatment
safety (34%), and a lack of guidelines for treatment (33%).4. Discussion
In order to effectively manage severe osteoporosis and its
associated (and increasing) morbidity, mortality, and eco-
nomic burden in South Korea, it is necessary to identify the
current issues in diagnosis and treatment faced by doctors
directly managing the disease. Although awareness of oste-
oporosis in general is increasing, much less information is
available on severe osteoporosis. To our knowledge, this is
the first study to survey doctors in South Korea on issues
associated specifically with severe osteoporosis. Our study
identified a number of important issues surrounding the
diagnosis and perception of severe osteoporosis, as well as
with each of the three drug classes most commonly used in
its treatment. Despite the perceived efficacy of PTH amongst
doctors surveyed, especially in the treatment of severe
51J.H. Kim et al. / Osteoporosis and Sarcopenia 2 (2016) 45e63osteoporosis, doctors indicated that prescription of PTH was
limited by its high cost and lack of reimbursement from the
National Health Insurance program. Addressing the issues
surrounding reimbursement of PTH may provide doctors
with more effective options for treatment, especially in cases
where previous treatments have proven ineffective or
unusable.
One of the most surprising findings in this survey was that
almost all doctors (89%) surveyed had concerns about treat-
ments for severe osteoporosis. The safety and efficacy of BPs,
the efficacy of SERMs, and the high cost of PTH were the
major concerns with each treatment. Doctors appeared to be
very aware of the safety issues surrounding BP use (necrosis
of the jaw and atypical femoral fracture) and the need to
switch to alternative treatments in preference to long-term BP
use [11]. Increased awareness of these safety issues was also
reflected in surveys of doctors in South Korea and other
countries in the Asia-Pacific region [8,12]. In terms of safety,
SERMs were viewed most favorably, as judged from doctors'
levels of satisfaction with this aspect of SERMs and their
preference for switching to SERMs following concerns with
the safety of BPs. However, the efficacy of SERMs, particu-
larly for treatment of severe osteoporosis, was perceived as
being lower than that of BPs and PTH (Fig. 2). For example,
raloxifene, a commonly prescribed SERM, has been suggested
to have reduced efficacy in reducing bone loss and fractures
compared with BPs [11]. Overall, PTH was viewed as having
the highest efficacy by doctors, specifically with regard to
increasing BMD and preventing further fracture. Despite
PTH's perceived efficacy, doctors viewed PTH as expensive,
particularly as its cost is not currently reimbursed by the
National Health Insurance program, in contrast to BPs and
SERMs. The high cost of PTH is likely to be a barrier to some
osteoporosis patients receiving effective treatment, particu-
larly those with severe osteoporosis, a higher proportion of
whom are prescribed PTH, compared with osteoporosis pa-
tients overall. Even after PTH treatment is initiated, in many
cases, its lack of affordability appears to result in prescriptions
being switched to BPs or SERMs. As a result, doctors often
felt that there were no alternatives when BPs and SERMs were
ineffective or unusable.
A lack of variety in treatment options was nominated by
50% of doctors as one of the points that needed improvement
in the management of severe osteoporosis. Given the risks
associated with long-term BP use, it is important that patients
are not maintained on BP treatment (especially if ineffective)
simply because there are no affordable alternatives. The high
cost of medicines has been identified as one of the major
barriers to optimal osteoporosis (including severe osteopo-
rosis) treatment in South Korea, the Asia-Pacific region, and
the United States [8,12,13]. Health insurance restrictions
were also seen as a major issue by doctors from Taiwan,
Indonesia, Thailand, and Vietnam [12]. Although PTH
treatment has been calculated to be cost-effective when
compared with no treatment [14], its cost-effectiveness
compared with other osteoporosis treatments, especiallyBPs, is yet to be conclusively established [15,16]. However,
PTH's perceived efficacy and apparent underutilization in the
current management of severe osteoporosis in South Korea
argue strongly for a re-examination of the reimbursement
criteria for osteoporosis treatments or for the development of
separate criteria to evaluate treatments for severe osteopo-
rosis. Increasing the affordability of PTH may have a sub-
stantial impact on improving disease management in South
Korea.
This study suggests that although doctors are aware of the
impact of severe osteoporosis on areas such as quality of life
and economic burden, they believe that there is much lower
awareness of these issues amongst patients and amongst so-
ciety as a whole. Previous surveys on osteoporosis in South
Korea, Asia, Britain, and the United States also identified a
lack of knowledge and awareness of the disease amongst pa-
tients as being one of the main barriers to effective disease
management [8,12,17,18]. Increasing awareness of osteopo-
rosis, especially amongst patients, may improve treatment and
management of the disease [19,20].
Interestingly, this survey indicates that there may be a lack of
awareness about the criteria for diagnosis of severe osteopo-
rosis, even amongst doctors treating the disease. The National
Institutes of Health in the US and the International Osteoporosis
Foundation both define severe osteoporosis as having a T-score
of2.5 or lower and at least one fracture, and these same criteria
are used in South Korea. However, some of the doctors surveyed
did not define severe osteoporosis using these criteria, stating
that classification of severe osteoporosis was only based on
either BMD or fracture alone. More than 40% of doctors also
stated that severe osteoporosis was indicated by a T-score of
3.0 or lower (instead of 2.5). Previous surveys have also
identified a lack of disease awareness amongst doctors as being
another barrier to optimal disease treatment [8,12].Not using the
relevant criteria may lead to misdiagnosis and failure to apply
the appropriate treatment. Further education of both doctors and
patients about osteoporosis, especially severe osteoporosis, may
improve disease diagnosis and management. Education pro-
grams aimed at orthopedic surgeons in South Korea have been
shown to improve the detection and treatment rate for osteo-
porosis following hip fracture [21].
To date, this study is the most comprehensive survey of the
opinions and practices of South Korean doctors (from various
specialties) with respect to their perception, diagnosis, and
treatment of severe osteoporosis. Another strength of this
study is that it provides insights into the use of leading
treatments for severe osteoporosis in real-world clinical
practice, as opposed to within the tightly controlled setting of a
clinical trial. The study also provides a qualitative comparison
of the efficacy, safety, and cost of BPs, SERMs, and PTH, as
perceived by doctors who regularly prescribe these medica-
tions. The limitations of this study include the small sample
size, the lack of comparative statistical analyses, and the fact
that the survey was not pre-tested. Another limitation was that
doctors were asked to estimate the numbers and percentages of
patients treated with various medications, as opposed to
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tabases, which may have led to recall bias. All the doctors
surveyed also practiced at large, urban hospitals, rather than
smaller hospitals or in rural areas.
5. Conclusion
In conclusion, this survey has identified a number of critical
issues surrounding the diagnosis and treatment of severe
osteoporosis in South Korea. Reassessment of the reimburse-
ment criteria for PTH treatment may be required in order to
provide doctors with much-needed treatment alternatives and
thereby maximize effective treatment of patients with severe
osteoporosis. Such measures, in combination with further
education of doctors and patients about the disease, are likely
to make a substantial impact on nationwide management of
this disease and the increasing disability, morbidity, and eco-
nomic burden resulting from it.
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Appendix A2. B. Perception
B. Perception 
Q9. What’s the definition of ‘severe osteoporosis’ to you? 
Please write down verbatim of respondent’s answer
___________________________________________________________________
____________________________________ 
Q10. When you diagnose ‘severe osteoporosis’, 
1) What are the level of each criteria that you consider as severe 
osteoporosis? 
2) Please rank criteria according to relative importance in diagnosing 
severe osteoporosis.  
1) Criteria 2) Importance 
1. Bone mineral 
density (BMD) BMD less than      - __ SD __________ 
2. Fracture More than  __ times __________ 
3. Age Aged more than __ years old __________ 
4. Others                  Please specify it: __________ 
Q11. Please rank treatment goal according to relative importance in severe 
osteoporosis. 
Importance
1. Prevention of further fracture  _________ 
2. Improvement of BMD  _________ 
3. Pain Relief  _________
4. Others (Please specify it: ____ ) _________ 
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* From Q12, define ‘severe osteoporosis’ in this study as ‘T-score is below -2.5’ and 
‘experienced at least one osteoporotic fracture’. 
Q12. Regarding severe osteoporosis,  
1) Personal perception – What are your personal scores on these 4 aspects:   
Seriousness of disease, Impact on Quality of Life (QOL), Economic burden, 
Urgency of Treatment? Please give scores using 5 point scales. 5 points means 
high and 1 point means low.  
1. Seriousness of disease 
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
2. Impact on QOL 
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
3. Economic Burden
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
4. Urgency of Treatment
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
2) Social perception - In your opinion, what are the scores of social perceptions 
on these 4 aspects: Seriousness of disease, Impact on QOL, Economic burden, 
Urgency of Treatment? 5 points means high and 1 point means low.
1. Seriousness of disease 
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
2. Impact on QOL 
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
3. Economic Burden
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
4. Urgency of Treatment
Low medium High 
1 ---------------- 2 ---------------- 3 ---------------- 4 ---------------5  
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1) Personal 2) Social 
1. Seriousness of disease Point(s) Point(s) 
2. Impact on QOL Point(s) Point(s) 
3. Economic Burden Point(s) Point(s) 
4. Urgency of Treatment Point(s) Point(s) 
Q13. What are the problems faced by severe osteoporotic patients whom you 
have treated in the last 6 months?  
Category Percentage (%) 
1. Death with related complications _____________/100% 
2. Necessity of long-term recuperation from 
surgical procedures and operations _____________/100% 
3. Economic difficulty  _____________/100% 
4. A serious level of malfunction 
causing discomforts in daily life _____________/100% 
5. Additional fracture happened  _____________/100% 
Q14. Currently, are there any concerns in prescribing medicines for severe 
osteoporotic patients?
oN.2seY.1
Q15. (Ask if answered ‘1. Yes’ in Q14) 
 Currently what are the concrete concerns in prescribing medicines for 
severe osteoporotic patients?  
Category Select all that apply 
1 1ytefaS
2 Efficacy  2 
3 Patient Compliance  3 
4 Price of medicines  4 
5 5srehtO
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Q16. (Ask reason for each category answered in Q15) 
What are the specific issues with ‘Safety/ Efficacy/ Patient Compliance/ 
Price of medicines’ that you face when prescribing treatment for severe 
osteoporosis patients? 
Category Reason 
1 ytefaS
2 Efficacy  
3 Patient Compliance  
4 Price of medicines  
5 srehtO
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Appendix A3. C. Current Practice
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Appendix A4. D. Current Practice
D. Unmet Needs 
Q21. Do you think treatment environments are different according to patient’s 
experience of osteoporotic fracture? 
Interviewer: when the respondent asks about ‘treatment environments’, please 
guide them to refer Q23 examples. 
oN.2seY.1
Q22. (Ask if answered ‘1. Yes’ in Q21) 
What are the details of differences in treatment environment according to 
patient’s experience of osteoporotic fracture?  
Probing points: probe question using Q23 examples. 
_________________________________________________________________
_________________________________________ 
Q23. * In your opinion, what are the points that need to be improved in the 
treatment of severe osteoporosis?   
Select all that apply 
1 1tnemesrubmierfonoitatimiL
2 2snoitpotnemtaertniyteiravfokcaL
3 Lack of recognition of patients on seriousness of disease  3 
4 Lack of systematic treatment guideline  4 
5 5ytefastuobasnrecnoC
6 6ycaciffetuobasnrecnoC
7 7):tiyficepsesaelP(srehtO
 Thank you 
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Treatments for Osteoporosis in South Korea 
tnemesrubmieRytilibaliavAtnemtaerT
Bisphosphonates 
seYseYetanordesiR
seYseYetanordnelA
seYseYetanordnabI
seYseYdicacinordeloZ
seYseYetanordimaP
ANoNetanordolC
Selective estrogen receptor modulators 
seYseYenefixolaR
seYseYenefixodezaB
Parathyroid hormone analogs 
oNseYeditarapireT
ANoN48-1enomrohdioryhtaraP
Vitamin D analogs 
Vitamin D/calcium supplements Yes Yes 
seYseYlodiclacaflA
seYseYlorticlaC
Other 
seYseYninotaclE
Estrogen replacement therapy Yes  Yes 
seYseY2KnimatiV
ANoNbamusoneD
ANoNetalenarmuitnortS
Abbreviation: NA, not applicable. 
Adapted from International Osteoporosis Foundation. Asia-Pacific Regional Audit. 2013 
[cited 2016 Jan 27]; Available from: 
http://www.iofbonehealth.org/sites/default/files/media/PDFs/Regional%20Audits/2013-
Asia_Pacific_Audit-Rep_Korea_0_0.pdf. Updated as of December 2015.
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